Subjects in the study were monitored using the LUX-Dx insertable cardiac monitor system to detect arrhythmia recurrence.

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Boston Scientific (NYSE: BSX) today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) ...

Kardium has revealed positive one-year efficacy results on its pulsed field ablation (PFA) device, the Globe PF System.

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Boston Scientific delivered strong first-quarter results, building on its hefty performance seen in 2024, as adoption of Farapulse and Watchman have impressed. Why it matters: Boston has exceeded ...

Boston Scientific will face more benign competition than previously feared when it comes to pulsed field ablation, according ...

"The data collected in this trial continues to support the FARAPULSE PFA System as a safe and effective therapy, now with evidence highlighting positive results for its use in treating patients ...

Q1 2025 Earnings Call Transcript April 23, 2025 Boston Scientific Corporation beats earnings expectations. Reported EPS is $0 ...

Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q1 CY2025, with sales up 20.9% ...